Haleon plc
Haleon plc (HLN.L) Stock Competitors & Peer Comparison
See (HLN.L) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HLN.L | £365.40 | +1.64% | 32.8B | 21.49 | £0.17 | +1.48% |
| HIK.L | £1,939.00 | -1.27% | 4.3B | 16.16 | £1.20 | +3.19% |
| HCM.L | £264.00 | -3.47% | 2.3B | -66.00 | -£0.04 | N/A |
| INDV.L | £1,238.00 | +1.56% | 1.5B | -309.50 | -£0.04 | N/A |
| 0IRF.IL | £6.94 | -1.50% | 1.2B | -11.96 | -£0.58 | N/A |
| AGY.L | £8.00 | +0.00% | 381.3M | -8.00 | -£0.01 | N/A |
| APH.L | £64.70 | +0.00% | 349.7M | -32.35 | -£0.02 | N/A |
| ANCR.L | £268.00 | -1.47% | 184.9M | 33.50 | £0.08 | +1.87% |
| BXP.L | £39.00 | +0.00% | 174M | 4.33 | £0.09 | +8.59% |
| BMK.L | £22.60 | +6.10% | 167.8M | -3.77 | -£0.06 | N/A |
Stock Comparison
HLN.L vs HIK.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, HIK.L has a market cap of 4.3B. Regarding current trading prices, HLN.L is priced at £365.40, while HIK.L trades at £1,939.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas HIK.L's P/E ratio is 16.16. In terms of profitability, HLN.L's ROE is +0.09%, compared to HIK.L's ROE of +0.16%. Regarding short-term risk, HLN.L is more volatile compared to HIK.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.Check HIK.L's competition here
HLN.L vs HCM.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, HCM.L has a market cap of 2.3B. Regarding current trading prices, HLN.L is priced at £365.40, while HCM.L trades at £264.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas HCM.L's P/E ratio is -66.00. In terms of profitability, HLN.L's ROE is +0.09%, compared to HCM.L's ROE of -0.01%. Regarding short-term risk, HLN.L is less volatile compared to HCM.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.Check HCM.L's competition here
HLN.L vs INDV.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, INDV.L has a market cap of 1.5B. Regarding current trading prices, HLN.L is priced at £365.40, while INDV.L trades at £1,238.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas INDV.L's P/E ratio is -309.50. In terms of profitability, HLN.L's ROE is +0.09%, compared to INDV.L's ROE of -0.01%. Regarding short-term risk, HLN.L is more volatile compared to INDV.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.Check INDV.L's competition here
HLN.L vs 0IRF.IL Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, 0IRF.IL has a market cap of 1.2B. Regarding current trading prices, HLN.L is priced at £365.40, while 0IRF.IL trades at £6.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas 0IRF.IL's P/E ratio is -11.96. In terms of profitability, HLN.L's ROE is +0.09%, compared to 0IRF.IL's ROE of -0.22%. Regarding short-term risk, HLN.L is more volatile compared to 0IRF.IL. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.Check 0IRF.IL's competition here
HLN.L vs AGY.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, AGY.L has a market cap of 381.3M. Regarding current trading prices, HLN.L is priced at £365.40, while AGY.L trades at £8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas AGY.L's P/E ratio is -8.00. In terms of profitability, HLN.L's ROE is +0.09%, compared to AGY.L's ROE of +20.72%. Regarding short-term risk, HLN.L is more volatile compared to AGY.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.Check AGY.L's competition here
HLN.L vs APH.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, APH.L has a market cap of 349.7M. Regarding current trading prices, HLN.L is priced at £365.40, while APH.L trades at £64.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas APH.L's P/E ratio is -32.35. In terms of profitability, HLN.L's ROE is +0.09%, compared to APH.L's ROE of -0.05%. Regarding short-term risk, HLN.L is more volatile compared to APH.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.Check APH.L's competition here
HLN.L vs ANCR.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, ANCR.L has a market cap of 184.9M. Regarding current trading prices, HLN.L is priced at £365.40, while ANCR.L trades at £268.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas ANCR.L's P/E ratio is 33.50. In terms of profitability, HLN.L's ROE is +0.09%, compared to ANCR.L's ROE of +0.31%. Regarding short-term risk, HLN.L is more volatile compared to ANCR.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.Check ANCR.L's competition here
HLN.L vs BXP.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, BXP.L has a market cap of 174M. Regarding current trading prices, HLN.L is priced at £365.40, while BXP.L trades at £39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas BXP.L's P/E ratio is 4.33. In terms of profitability, HLN.L's ROE is +0.09%, compared to BXP.L's ROE of +0.13%. Regarding short-term risk, HLN.L is more volatile compared to BXP.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.Check BXP.L's competition here
HLN.L vs BMK.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, BMK.L has a market cap of 167.8M. Regarding current trading prices, HLN.L is priced at £365.40, while BMK.L trades at £22.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas BMK.L's P/E ratio is -3.77. In terms of profitability, HLN.L's ROE is +0.09%, compared to BMK.L's ROE of +0.19%. Regarding short-term risk, HLN.L is less volatile compared to BMK.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.Check BMK.L's competition here
HLN.L vs 0W1Q.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, 0W1Q.L has a market cap of 81.3M. Regarding current trading prices, HLN.L is priced at £365.40, while 0W1Q.L trades at £19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas 0W1Q.L's P/E ratio is -9.08. In terms of profitability, HLN.L's ROE is +0.09%, compared to 0W1Q.L's ROE of +0.11%. Regarding short-term risk, HLN.L is less volatile compared to 0W1Q.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.Check 0W1Q.L's competition here
HLN.L vs VLG.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, VLG.L has a market cap of 78.4M. Regarding current trading prices, HLN.L is priced at £365.40, while VLG.L trades at £61.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas VLG.L's P/E ratio is 61.25. In terms of profitability, HLN.L's ROE is +0.09%, compared to VLG.L's ROE of -0.00%. Regarding short-term risk, HLN.L is less volatile compared to VLG.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.Check VLG.L's competition here
HLN.L vs EAH.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, EAH.L has a market cap of 50.5M. Regarding current trading prices, HLN.L is priced at £365.40, while EAH.L trades at £74.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas EAH.L's P/E ratio is 37.25. In terms of profitability, HLN.L's ROE is +0.09%, compared to EAH.L's ROE of +0.01%. Regarding short-term risk, HLN.L is more volatile compared to EAH.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.Check EAH.L's competition here
HLN.L vs STX.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, STX.L has a market cap of 46.9M. Regarding current trading prices, HLN.L is priced at £365.40, while STX.L trades at £4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas STX.L's P/E ratio is -2.25. In terms of profitability, HLN.L's ROE is +0.09%, compared to STX.L's ROE of +68.33%. Regarding short-term risk, HLN.L is less volatile compared to STX.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.Check STX.L's competition here
HLN.L vs PXS.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, PXS.L has a market cap of 17.6M. Regarding current trading prices, HLN.L is priced at £365.40, while PXS.L trades at £0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas PXS.L's P/E ratio is N/A. In terms of profitability, HLN.L's ROE is +0.09%, compared to PXS.L's ROE of -0.59%. Regarding short-term risk, HLN.L is less volatile compared to PXS.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.Check PXS.L's competition here
HLN.L vs CHLL.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, CHLL.L has a market cap of 10.9M. Regarding current trading prices, HLN.L is priced at £365.40, while CHLL.L trades at £2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas CHLL.L's P/E ratio is -2.15. In terms of profitability, HLN.L's ROE is +0.09%, compared to CHLL.L's ROE of -3.55%. Regarding short-term risk, HLN.L is more volatile compared to CHLL.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.Check CHLL.L's competition here
HLN.L vs MXC.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, MXC.L has a market cap of 9.3M. Regarding current trading prices, HLN.L is priced at £365.40, while MXC.L trades at £21.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas MXC.L's P/E ratio is -0.13. In terms of profitability, HLN.L's ROE is +0.09%, compared to MXC.L's ROE of +26.60%. Regarding short-term risk, HLN.L is less volatile compared to MXC.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.Check MXC.L's competition here
HLN.L vs CEL.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, CEL.L has a market cap of 9.2M. Regarding current trading prices, HLN.L is priced at £365.40, while CEL.L trades at £13.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas CEL.L's P/E ratio is -1.67. In terms of profitability, HLN.L's ROE is +0.09%, compared to CEL.L's ROE of -1.43%. Regarding short-term risk, HLN.L is more volatile compared to CEL.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.Check CEL.L's competition here
HLN.L vs RGT.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, RGT.L has a market cap of 4.2M. Regarding current trading prices, HLN.L is priced at £365.40, while RGT.L trades at £6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas RGT.L's P/E ratio is -0.26. In terms of profitability, HLN.L's ROE is +0.09%, compared to RGT.L's ROE of +4.20%. Regarding short-term risk, HLN.L is less volatile compared to RGT.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.Check RGT.L's competition here
HLN.L vs N4P.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, N4P.L has a market cap of 3.7M. Regarding current trading prices, HLN.L is priced at £365.40, while N4P.L trades at £0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas N4P.L's P/E ratio is -0.45. In terms of profitability, HLN.L's ROE is +0.09%, compared to N4P.L's ROE of -0.89%. Regarding short-term risk, HLN.L is less volatile compared to N4P.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.Check N4P.L's competition here
HLN.L vs HELD.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, HELD.L has a market cap of 1.4M. Regarding current trading prices, HLN.L is priced at £365.40, while HELD.L trades at £0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas HELD.L's P/E ratio is N/A. In terms of profitability, HLN.L's ROE is +0.09%, compared to HELD.L's ROE of -3.64%. Regarding short-term risk, HLN.L is more volatile compared to HELD.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.Check HELD.L's competition here
HLN.L vs 0A4X.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, 0A4X.L has a market cap of 10. Regarding current trading prices, HLN.L is priced at £365.40, while 0A4X.L trades at £0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas 0A4X.L's P/E ratio is -0.00. In terms of profitability, HLN.L's ROE is +0.09%, compared to 0A4X.L's ROE of N/A. Regarding short-term risk, HLN.L is more volatile compared to 0A4X.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.Check 0A4X.L's competition here
HLN.L vs DNL.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, DNL.L has a market cap of 0. Regarding current trading prices, HLN.L is priced at £365.40, while DNL.L trades at £27.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas DNL.L's P/E ratio is -0.03. In terms of profitability, HLN.L's ROE is +0.09%, compared to DNL.L's ROE of -0.59%. Regarding short-term risk, Volatility data is not available for a full comparison. HLN.L has daily volatility of 3.06 and DNL.L has daily volatility of N/A.Check DNL.L's competition here
HLN.L vs AMYT.L Comparison August 2025
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 32.8B. In comparison, AMYT.L has a market cap of 0. Regarding current trading prices, HLN.L is priced at £365.40, while AMYT.L trades at £143.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 21.49, whereas AMYT.L's P/E ratio is -0.04. In terms of profitability, HLN.L's ROE is +0.09%, compared to AMYT.L's ROE of -1.07%. Regarding short-term risk, HLN.L is less volatile compared to AMYT.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.Check AMYT.L's competition here